Cephalon, Inc. Case Solution In early 1997, Cephalon, awaited an FDA panel’s conclusion on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might want considerable additional funds to commercialize and to purchase the rights again. The CFO of the firm is contemplating various funding strategies, including paying for those options […]